Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yuqian Liao, Yulu Liao, Jun Li, Yong Li & Ying Fan. (2023) The Prognostic Role of HuR Varies Between Different Subtypes of Breast Cancer Patients: Data Mining and Retrospective Analysis. Breast Cancer: Targets and Therapy 15, pages 135-146.
Read now
Read now
Sheikh Mohammad Umar, Sushmita Patra, Akanksha Kashyap, Arundhathi Dev J R, Lalit Kumar & Chandra Prakash Prasad. (2022) Quercetin Impairs HuR-Driven Progression and Migration of Triple Negative Breast Cancer (TNBC) Cells. Nutrition and Cancer 74:4, pages 1497-1510.
Read now
Read now
Articles from other publishers (71)
Jennifer M. Finan, Thomas L. Sutton, Dan A. Dixon & Jonathan R. Brody. (2023) Targeting the RNA-Binding Protein HuR in Cancer. Cancer Research 83:21, pages 3507-3516.
Crossref
Crossref
Darius Stukas, Aldona Jasukaitiene, Arenida Bartkeviciene, Jason Matthews, Toivo Maimets, Indrek Teino, Kristaps Jaudzems, Antanas Gulbinas & Zilvinas Dambrauskas. (2023) Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway. International Journal of Molecular Sciences 24:17, pages 13155.
Crossref
Crossref
Benjamin Philipp Joseph, Verena Weber, Lisa Knüpfer, Alejandro Giorgetti, Mercedes Alfonso-Prieto, Sybille Krauß, Paolo Carloni & Giulia Rossetti. (2023) Low Molecular Weight Inhibitors Targeting the RNA-Binding Protein HuR. International Journal of Molecular Sciences 24:17, pages 13127.
Crossref
Crossref
Zheng Li, Yaming Li, Dianwen Han, Xiaolong Wang, Chen Li, Tong Chen, Wenhao Li, Yiran Liang, Dan Luo, Bing Chen, Lijuan Wang, Wenjing Zhao & Qifeng Yang. (2023) circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells. Cell Death & Disease 14:7.
Crossref
Crossref
Lanjing Wei, Qi Zhang, Cuncong Zhong, Lily He, Yuxia Zhang, Ahlam M. Armaly, Jeffrey Aubé, Danny R. Welch, Liang Xu & Xiaoqing Wu. (2023)
Functional inhibition of the
RNA
‐binding protein
HuR
sensitizes triple‐negative breast cancer to chemotherapy
. Molecular Oncology.
Crossref
Crossref
Meghna Mehta, Rajeswari Raguraman, Rajagopal Ramesh & Anupama Munshi. (2022) RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer. Advanced Drug Delivery Reviews 191, pages 114569.
Crossref
Crossref
Wei Li, Xiaolan Deng & Jianjun Chen. (2022) RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Seminars in Cancer Biology 86, pages 664-677.
Crossref
Crossref
Yanyan Wang, Yun-Ling Tai, Grayson Way, Jing Zeng, Derrick Zhao, Lianyong Su, Xixian Jiang, Kaitlyn G. Jackson, Xuan Wang, Emily C. Gurley, Jinze Liu, Jinpeng Liu, Weidong Chen, Xiang-Yang Wang, Arun J. Sanyal, Phillip B. Hylemon & Huiping Zhou. (2022) RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression. Cell & Bioscience 12:1.
Crossref
Crossref
Mengmeng Yu, Yuxing Qu, Haili Zhang & Xiaojun Wang. (2022) Roles of ANP32 proteins in cell biology and viral replication. Animal Diseases 2:1.
Crossref
Crossref
Ying Chen, Hai Qin & Lufeng Zheng. (2022) Research progress on RNA−binding proteins in breast cancer. Frontiers in Oncology 12.
Crossref
Crossref
Xiaoqing Wu & Liang Xu. (2022) The RNA-binding protein HuR in human cancer: A friend or foe?. Advanced Drug Delivery Reviews 184, pages 114179.
Crossref
Crossref
Haijian Cai, Dandan Zheng, Yizhu Yao, Lehe Yang, Xiaoying Huang & Liangxing Wang. (2022) Roles of Embryonic Lethal Abnormal Vision-Like RNA Binding Proteins in Cancer and Beyond. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Dimitrios Goutas, Alexandros Pergaris, Constantinos Giaginis & Stamatios Theocharis. (2022) HuR as Therapeutic Target in Cancer: What the Future Holds. Current Medicinal Chemistry 29:1, pages 56-65.
Crossref
Crossref
Natalia Filippova, Xiuhua Yang, Subramaniam Ananthan, Jennifer Calano, Vibha Pathak, Larry Bratton, Rakesh H. Vekariya, Sixue Zhang, Edward Ofori, Emily N. Hayward, David Namkoong, David K. Crossman, Michael R. Crowley, Peter H. King, James Mobley & Louis B. Nabors. (2021) Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors. Cancer Research 81:8, pages 2220-2233.
Crossref
Crossref
Natalia Filippova & Louis B. Nabors. (2020) ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity. Cancers 12:10, pages 3069.
Crossref
Crossref
Christopher W. Schultz, Ranjan Preet, Teena Dhir, Dan A. Dixon & Jonathan R. Brody. (2020) Understanding and targeting the disease‐related RNA binding protein human antigen R (HuR). WIREs RNA 11:3.
Crossref
Crossref
Daniel Andrade, Meghna Mehta, James Griffith, Sangphil Oh, Joshua Corbin, Anish Babu, Supriyo De, Allshine Chen, Yan D. Zhao, Sanam Husain, Sudeshna Roy, Liang Xu, Jeffrey Aube, Ralf Janknecht, Myriam Gorospe, Terence Herman, Rajagopal Ramesh & Anupama Munshi. (2019) HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A. Cancers 11:12, pages 2014.
Crossref
Crossref
Jian Cai, Huaiming Wang, Xiaodong Jiao, Rongkang Huang, Qiyuan Qin, Jianwei Zhang, Honglei Chen, Dan Feng, Xin Tian & Hui Wang. (2019) The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6. Molecular Cancer Therapeutics 18:7, pages 1243-1254.
Crossref
Crossref
Mingxia Wu, Christy W.S. Tong, Wei Yan, Kenneth K.W. To & William C.S. Cho. (2019) The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy. Current Cancer Drug Targets 19:5, pages 382-399.
Crossref
Crossref
Kazuhiro Toyota, Yoshiaki Murakami, Naru Kondo, Kenichiro Uemura, Naoya Nakagawa, Shinya Takahashi & Taijiro Sueda. (2018) Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy. Annals of Surgical Oncology 25:5, pages 1202-1210.
Crossref
Crossref
Georgia Levidou, Ioly Kotta-Loizou, Jason Tasoulas, Thomas Papadopoulos & Stamatios Theocharis. (2018) Clinical Significance and Biological Role of HuR in Head and Neck Carcinomas. Disease Markers 2018, pages 1-13.
Crossref
Crossref
Guan-Liang Lin, Huei-Ju Ting, Ta-Chien Tseng, Vivian Juang & Yu-Li Lo. (2017) Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLOS ONE 12:10, pages e0185625.
Crossref
Crossref
Ranganayaki Muralidharan, Meghna Mehta, Rebaz Ahmed, Sudeshna Roy, Liang Xu, Jeffrey Aubé, Allshine Chen, Yan Daniel Zhao, Terence Herman, Rajagopal Ramesh & Anupama Munshi. (2017) HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Scientific Reports 7:1.
Crossref
Crossref
Sheng Tan, Keshuo Ding, Qing-Yun Chong, Junsong Zhao, Yuan Liu, Yunying Shao, Yuanyuan Zhang, Qing Yu, Zirui Xiong, Weijie Zhang, Min Zhang, Gaopeng Li, Xiaoni Li, Xiangjun Kong, Akhlaq Ahmad, Zhengsheng Wu, Qiang Wu, Xiaodong Zhao, Peter E. Lobie & Tao Zhu. (2017) Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Journal of Biological Chemistry 292:33, pages 13551-13564.
Crossref
Crossref
Jaclyn F. Hechtman & Christine Iacobuzio-Donahue. 2017. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set
139
149.e3
.
John Henry Barbe, Kevin M. O’Hayer & Jonathan R. Brody. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
693
705
.
Fernando F. Blanco, Ranjan Preet, Andrea Aguado, Vikalp Vishwakarma, Laura E. Stevens, Alok Vyas, Subhash Padhye, Liang Xu, Scott J. Weir, Shrikant Anant, Nicole Meisner-Kober, Jonathan R. Brody & Dan A. Dixon. (2016) Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget 7:45, pages 74043-74058.
Crossref
Crossref
Ioly Kotta-Loizou, Spyridon N. Vasilopoulos, Robert H.A. Coutts & Stamatios Theocharis. (2016) Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment. Neoplasia 18:11, pages 674-688.
Crossref
Crossref
Meghna Mehta, Kanthesh Basalingappa, James N. Griffith, Daniel Andrade, Anish Babu, Narsireddy Amreddy, Ranganayaki Muralidharan, Myriam Gorospe, Terence Herman, Wei-Qun Ding, Rajagopal Ramesh & Anupama Munshi. (2016) HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget 7:40, pages 64820-64835.
Crossref
Crossref
Yu-Hung Huang, Weidan Peng, Narumi Furuuchi, Jacquelyn Gerhart, Kelly Rhodes, Neelanjan Mukherjee, Masaya Jimbo, Gregory E. Gonye, Jonathan R. Brody, Robert C. Getts & Janet A. Sawicki. (2016) Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth. Cancer Research 76:6, pages 1549-1559.
Crossref
Crossref
Jingjing Ge, Na Chang, Zhongxin Zhao, Lei Tian, Xianghui Duan, Lin Yang & Liying Li. (2016) Essential Roles of RNA-binding Protein HuR in Activation of Hepatic Stellate Cells Induced by Transforming Growth Factor-β1. Scientific Reports 6:1.
Crossref
Crossref
C. Zurla, J. Jung & P. J. Santangelo. (2016) Can we observe changes in mRNA “state”? Overview of methods to study mRNA interactions with regulatory proteins relevant in cancer related processes. The Analyst 141:2, pages 548-562.
Crossref
Crossref
Constantinos Giaginis, Paraskevi Alexandrou, Ioanna Delladetsima, Ioannis Karavokyros, Eugene Danas, Athina Giagini, Efstratios Patsouris & Stamatios Theocharis. (2015) Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions. Pathology & Oncology Research 22:1, pages 189-196.
Crossref
Crossref
John Henry Barbe, Kevin M. O’Hayer & Jonathan R. Brody. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
13
.
Zhonghua Wang, Akash Bhattacharya & Dmitri N. Ivanov. (2015) Identification of Small-Molecule Inhibitors of the HuR/RNA Interaction Using a Fluorescence Polarization Screening Assay Followed by NMR Validation. PLOS ONE 10:9, pages e0138780.
Crossref
Crossref
Aldona Jakstaite. (2015) HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World Journal of Gastroenterology 21:46, pages 13004.
Crossref
Crossref
Constantinos Giaginis, Paraskevi Alexandrou, Nikolaos Tsoukalas, Ioannis Sfiniadakis, Nikolaos Kavantzas, Emmanuel Agapitos, Efstratios Patsouris & Stamatios Theocharis. (2014) Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small-cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. Tumor Biology 36:1, pages 315-327.
Crossref
Crossref
Ranganayaki Muralidharan, Anish Babu, Kanthesh Basalingappa, Meghna Mehta, Anupama Munshi & Rajagopal Ramesh. 2015. Multi-Targeted Approach to Treatment of Cancer. Multi-Targeted Approach to Treatment of Cancer
277
294
.
Dandan Wang, Min Wang, Chang’e Hu, Ting Shuang, Yingying Zhou & Xiaoyu Yan. (2014) Expression of the ELAV-like protein HuR in the cytoplasm is associated with endometrial carcinoma progression. Tumor Biology 35:12, pages 11939-11947.
Crossref
Crossref
Patrick T. Reilly, Yun Yu, Ali Hamiche & Lishun Wang. (2014) Cracking the ANP32 whips: Important functions, unequal requirement, and hints at disease implications. BioEssays 36:11, pages 1062-1071.
Crossref
Crossref
Ioly Kotta-Loizou, Constantinos Giaginis & Stamatios Theocharis. (2014) Clinical significance of HuR expression in human malignancy. Medical Oncology 31:9.
Crossref
Crossref
Shruti Lal, Richard A. Burkhart, Neil Beeharry, Vikram Bhattacharjee, Eric R. Londin, Joseph A. Cozzitorto, Carmella Romeo, Masaya Jimbo, Zoë A. Norris, Charles J. Yeo, Janet A. Sawicki, Jordan M. Winter, Isidore Rigoutsos, Timothy J. Yen & Jonathan R. Brody. (2014) HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Research 74:4, pages 1128-1140.
Crossref
Crossref
Cong Zhang, Guoliang Xue, Jingwang Bi, Ming Geng, Huili Chu, Yaping Guan, Jun Wang & Baocheng Wang. (2013) Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma. Tumor Biology 35:1, pages 73-80.
Crossref
Crossref
Jun Wang, Dali Li, Baocheng Wang & Yun Wu. (2013) Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 141:2, pages 213-224.
Crossref
Crossref
Hoin Kang, Chongtae Kim, Heejin Lee, Wook Kim & Eun Lee. (2013) Post-Transcriptional Controls by Ribonucleoprotein Complexes in the Acquisition of Drug Resistance. International Journal of Molecular Sciences 14:8, pages 17204-17220.
Crossref
Crossref
Zhongpeng Zhu, Baocheng Wang, Jingwang Bi, Cong Zhang, Yan Guo, Huili Chu, Xiuju Liang, Chen Zhong & Jun Wang. (2013) Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumor Biology 34:4, pages 2299-2308.
Crossref
Crossref
Diane Moujalled, Janine L. James, Sarah J. Parker, Grace E. Lidgerwood, Clare Duncan, Jodi Meyerowitz, Takashi Nonaka, Masato Hasegawa, Katja M. Kanninen, Alexandra Grubman, Jeffrey R. Liddell, Peter J. Crouch & Anthony R. White. (2013) Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress. PLoS ONE 8:6, pages e67433.
Crossref
Crossref
Jun Wang, Yan Guo, Huili Chu, Yaping Guan, Jingwang Bi & Baocheng Wang. (2013) Multiple Functions of the RNA-Binding Protein HuR in Cancer Progression, Treatment Responses and Prognosis. International Journal of Molecular Sciences 14:5, pages 10015-10041.
Crossref
Crossref
Elisa Latorre, Toma Tebaldi, Gabriella Viero, Antonino Maria Spartà, Alessandro Quattrone & Alessandro Provenzani. (2012) Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Molecular Cancer 11:1.
Crossref
Crossref
John L McElwee, Sunish Mohanan, Obi L Griffith, Heike C Breuer, Lynne J Anguish, Brian D Cherrington, Ashley M Palmer, Louise R Howe, Venkataraman Subramanian, Corey P Causey, Paul R Thompson, Joe W Gray & Scott A Coonrod. (2012) Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer 12:1.
Crossref
Crossref
Andrew Barker, Michael R. Epis, Corrine J. Porter, Benjamin R. Hopkins, Matthew C. J. Wilce, Jackie A. Wilce, Keith M. Giles & Peter J. Leedman. (2012) Sequence requirements for RNA binding by HuR and AUF1. The Journal of Biochemistry 151:4, pages 423-437.
Crossref
Crossref
Jacqueline C. Shultz & Charles E. Chalfant. (2012) The flip-flop HuR: part of the problem or the solution in fighting cancer?. Journal of Clinical Investigation 122:1, pages 16-19.
Crossref
Crossref
Weijun Dai, Gen Zhang & Eugene V. Makeyev. (2012) RNA-binding protein HuR autoregulates its expression by promoting alternative polyadenylation site usage. Nucleic Acids Research 40:2, pages 787-800.
Crossref
Crossref
Jonathan R. Brody, David W. Rittenhouse, Agnieszka K. Witkiewicz & Charles J. Yeo. 2012. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract. Blumgart's Surgery of the Liver, Pancreas and Biliary Tract
123
134.e3
.
Jodi Meyerowitz, Sarah J Parker, Laura J Vella, Dominic CH Ng, Katherine A Price, Jeffrey R Liddell, Aphrodite Caragounis, Qiao-Xin Li, Colin L Masters, Takashi Nonaka, Masato Hasegawa, Marie A Bogoyevitch, Katja M Kanninen, Peter J Crouch & Anthony R White. (2011) C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Molecular Neurodegeneration 6:1.
Crossref
Crossref
Michael R. Epis, Andrew Barker, Keith M. Giles, Dianne J. Beveridge & Peter J. Leedman. (2011) The RNA-binding Protein HuR Opposes the Repression of ERBB-2 Gene Expression by MicroRNA miR-331-3p in Prostate Cancer Cells. Journal of Biological Chemistry 286:48, pages 41442-41454.
Crossref
Crossref
Wei‐Ning Lin, Chih‐Chung Lin, Hsin‐Yi Cheng & Chuen‐Mao Yang. (2011)
Regulation of cyclooxygenase‐2 and cytosolic phospholipase A
2
gene expression by lipopolysaccharide through the RNA‐binding protein HuR: involvement of NADPH oxidase, reactive oxygen species and mitogen‐activated protein kinases
. British Journal of Pharmacology 163:8, pages 1691-1706.
Crossref
Crossref
Mira Heinonen, Annabrita Hemmes, Kaisa Salmenkivi, Kotb Abdelmohsen, Suvi‐Tuuli Vilén, Marko Laakso, Marjut Leidenius, Tuula Salo, Sampsa Hautaniemi, Myriam Gorospe, Päivi Heikkilä, Caj Haglund & Ari Ristimäki. (2011)
Role of RNA binding protein HuR in ductal carcinoma
in situ
of the breast
. The Journal of Pathology 224:4, pages 529-539.
Crossref
Crossref
C Spagnuolo, C Cerella, M Russo, S Chateauvieux, M Diederich & G L Russo. (2011) Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. British Journal of Cancer 105:2, pages 221-230.
Crossref
Crossref
Jonathan R. Brody & Gregory E. Gonye. (2011) HuR's role in gemcitabine efficacy: an exception or opportunity?. Wiley Interdisciplinary Reviews: RNA 2:3, pages 435-444.
Crossref
Crossref
Robert Calaluce, Matthew M Gubin, J Wade Davis, Joseph D Magee, Jing Chen, Yuki Kuwano, Myriam Gorospe & Ulus Atasoy. (2010) The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer 10:1.
Crossref
Crossref
Timothy K. Williams, Christina L. Costantino, Nikolai A. Bildzukewicz, Nathan G. Richards, David W. Rittenhouse, Lisa Einstein, Joseph A. Cozzitorto, Judith C. Keen, Abhijit Dasgupta, Myriam Gorospe, Gregory E. Gonye, Charles J. Yeo, Agnieszka K. Witkiewicz & Jonathan R. Brody. (2010) pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs. PLoS ONE 5:11, pages e15455.
Crossref
Crossref
Nathan G. Richards, David W. Rittenhouse, Boris Freydin, Joseph A. Cozzitorto, Dane Grenda, Hallgeir Rui, Greg Gonye, Eugene P. Kennedy, Charles J. Yeo, Jonathan R. Brody & Agnieszka K. Witkiewicz. (2010) HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. Annals of Surgery 252:3, pages 499-506.
Crossref
Crossref
Kotb Abdelmohsen & Myriam Gorospe. (2010) Posttranscriptional regulation of cancer traits by HuR. WIREs RNA 1:2, pages 214-229.
Crossref
Crossref
Giuseppina Raspaglio, Ilaria De Maria, Flavia Filippetti, Enrica Martinelli, Gian Franco Zannoni, Silvia Prislei, Gabriella Ferrandina, Shohreh Shahabi, Giovanni Scambia & Cristiano Ferlini. (2010) HuR Regulates β-Tubulin Isotype Expression in Ovarian Cancer. Cancer Research 70:14, pages 5891-5900.
Crossref
Crossref
Lauren A. Licata, Christine L. Hostetter, James Crismale, Anjali Sheth & Judith Clancy Keen. (2009) The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Research and Treatment 122:1, pages 55-63.
Crossref
Crossref
Jürgen Veeck & Manel Esteller. (2010) Breast Cancer Epigenetics: From DNA Methylation to microRNAs. Journal of Mammary Gland Biology and Neoplasia 15:1, pages 5-17.
Crossref
Crossref
Nicole-Claudia Meisner & Witold Filipowicz. 2010. Regulation of microRNAs. Regulation of microRNAs
106
123
.
Jonathan R BrodyAgnieszka K Witkiewicz, Charles J Yeo, Myriam Gorospe & Judith C Keen. (2009) The ‘RNA-binding ome’: future implications for chemotherapeutic efficacy. Future Oncology 5:9, pages 1317-1319.
Crossref
Crossref
Christina L. Costantino, Agnieszka K. Witkiewicz, Yuki Kuwano, Joseph A. Cozzitorto, Eugene P. Kennedy, Abhijit Dasgupta, Judith C. Keen, Charles J. Yeo, Myriam Gorospe & Jonathan R. Brody. (2009) The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase. Cancer Research 69:11, pages 4567-4572.
Crossref
Crossref
Christine L. Hostetter, Lauren A. Licata & Judith Clancy Keen. (2009) Timing is everything: Order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Letters 275:2, pages 178-184.
Crossref
Crossref